ABCL offering history
Every offering-related filing in AbCellera Biologics Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 315 filings back to Apr 6, 2017.
| Date | Filing | What it means | |
|---|---|---|---|
| Aug 11, 2026 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 27, 2025 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Aug 11, 2022 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Feb 25, 2022 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Feb 16, 2022 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Dec 7, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Dec 7, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Nov 12, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Nov 4, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Sep 23, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Sep 15, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Aug 17, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Jul 15, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Jun 25, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Jun 22, 2021 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Jun 21, 2021 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jun 10, 2021 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
| Dec 14, 2020 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Dec 10, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Dec 10, 2020 | S-1MEF → | REGISTERED | S-1MEF registration — capacity to sell shares, not a sale yet |
| Dec 10, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Dec 7, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Nov 25, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Nov 20, 2020 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
ABCL offering FAQ
When did ABCL last execute an offering?
Per SEC filings, AbCellera Biologics Inc.'s most recent priced offering document is a 424B5 filed 2026-08-11. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did ABCL last announce or register an offering?
The most recent registration is a S-3ASR filed 2025-02-27. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.